



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	1.98
Trade Time:	8:00 PM ET 10/18/17
Change:	-0.03 ↓ (1.493%)
Day Range	1.97 - 2.09
52-Week Range	1.27 - 7.10
Volume	434,156


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [10/13/17
Rexahn Announces \\$8 Million Registered Direct Offering](#)
- [10/10/17
Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117](#)
- [09/21/17
Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC](#)
- [09/11/17
Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology \(ESMO\) Congress](#)
- [09/10/17
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology \(ESMO\) Congress](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- [02/24/17
Annual Report \(10-K\)](#)
- [02/24/17
Proxy Statement \(DEF 14A\)](#)
- [08/04/17
Quarterly Report \(10-Q\)](#)
- [05/03/17
Quarterly Report \(10-Q\)](#)
- [11/04/16
Quarterly Report \(10-Q\)](#)